Jessica M Fogel1, Mariya V Sivay, Vanessa Cummings, Ethan A Wilson, Stephen Hart, Theresa Gamble, Oliver Laeyendecker, Reinaldo E Fernandez, Carlos Del Rio, D Scott Batey, Kenneth H Mayer, Jason E Farley, Laura McKinstry, James P Hughes, Robert H Remien, Chris Beyrer, Susan H Eshleman. 1. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland Fred Hutchinson Cancer Research Center, Seattle, Washington Frontier Science Foundation, Amherst, New York FHI 360, Durham, North Carolina NIAID, National Institutes of Health Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland Emory University Rollins School of Public Health and School of Medicine, Atlanta, Georgia Department of Social Work, University of Alabama at Birmingham, Birmingham, Alabama Department of Medicine, Harvard Medical School Fenway Institute, Boston, Massachusetts Johns Hopkins University School of Nursing, Baltimore, Maryland Department of Biostatistics, University of Washington, Seattle, Washington HIV Center for Clinical and Behavioral Studies, NY State Psychiatric Institute and Columbia University, New York, New York Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Abstract
OBJECTIVE: To analyze HIV drug resistance among MSM recruited for participation in the HPTN 078 study, which evaluated methods for achieving and maintaining viral suppression in HIV-infected MSM. METHODS: Individuals were recruited at four study sites in the United States (Atlanta, Georgia; Baltimore, Maryland; Birmingham, Alabama; and Boston, Massachusetts; 2016-2017). HIV genotyping was performed using samples collected at study screening or enrollment. HIV drug resistance was evaluated using the Stanford v8.7 algorithm. A multiassay algorithm was used to identify individuals with recent HIV infection. Clustering of HIV sequences was evaluated using phylogenetic methods. RESULTS: High-level HIV drug resistance was detected in 44 (31%) of 142 individuals (Atlanta: 21%, Baltimore: 29%, Birmingham: 53%, Boston: 26%); 12% had multiclass resistance, 16% had resistance to tenofovir or emtricitabine, and 8% had resistance to integrase strand transfer inhibitors (INSTIs); 3% had intermediate-level resistance to second-generation INSTIs. In a multivariate model, self-report of ever having been on antiretroviral therapy (ART) was associated with resistance (P = 0.005). One of six recently infected individuals had drug resistance. Phylogenetic analysis identified five clusters of study sequences; two clusters had shared resistance mutations. CONCLUSION: High prevalence of drug resistance was observed among MSM. Some had multiclass resistance, resistance to drugs used for preexposure prophylaxis (PrEP), and INSTI resistance. These findings highlight the need for improved HIV care in this high-risk population, identification of alternative regimens for PrEP, and inclusion of integrase resistance testing when selecting ART regimens for MSM in the United States.
OBJECTIVE: To analyze HIV drug resistance among MSM recruited for participation in the HPTN 078 study, which evaluated methods for achieving and maintaining viral suppression in HIV-infected MSM. METHODS: Individuals were recruited at four study sites in the United States (Atlanta, Georgia; Baltimore, Maryland; Birmingham, Alabama; and Boston, Massachusetts; 2016-2017). HIV genotyping was performed using samples collected at study screening or enrollment. HIV drug resistance was evaluated using the Stanford v8.7 algorithm. A multiassay algorithm was used to identify individuals with recent HIV infection. Clustering of HIV sequences was evaluated using phylogenetic methods. RESULTS: High-level HIV drug resistance was detected in 44 (31%) of 142 individuals (Atlanta: 21%, Baltimore: 29%, Birmingham: 53%, Boston: 26%); 12% had multiclass resistance, 16% had resistance to tenofovir or emtricitabine, and 8% had resistance to integrase strand transfer inhibitors (INSTIs); 3% had intermediate-level resistance to second-generation INSTIs. In a multivariate model, self-report of ever having been on antiretroviral therapy (ART) was associated with resistance (P = 0.005). One of six recently infected individuals had drug resistance. Phylogenetic analysis identified five clusters of study sequences; two clusters had shared resistance mutations. CONCLUSION: High prevalence of drug resistance was observed among MSM. Some had multiclass resistance, resistance to drugs used for preexposure prophylaxis (PrEP), and INSTI resistance. These findings highlight the need for improved HIV care in this high-risk population, identification of alternative regimens for PrEP, and inclusion of integrase resistance testing when selecting ART regimens for MSM in the United States.
Authors: Christopher S Murrill; Trista Bingham; Jennifer Lauby; Kai-Lih Liu; Darrell Wheeler; Alex Carballo-Diéguez; Gary Marks; Gregorio A Millett Journal: J Natl Med Assoc Date: 2016-02 Impact factor: 1.798
Authors: Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2018-07-24 Impact factor: 56.272
Authors: David A Margolis; Juan Gonzalez-Garcia; Hans-Jürgen Stellbrink; Joseph J Eron; Yazdan Yazdanpanah; Daniel Podzamczer; Thomas Lutz; Jonathan B Angel; Gary J Richmond; Bonaventura Clotet; Felix Gutierrez; Louis Sloan; Marty St Clair; Miranda Murray; Susan L Ford; Joseph Mrus; Parul Patel; Herta Crauwels; Sandy K Griffith; Kenneth C Sutton; David Dorey; Kimberly Y Smith; Peter E Williams; William R Spreen Journal: Lancet Date: 2017-07-24 Impact factor: 79.321
Authors: Pamina M Gorbach; Marjan Javanbakht; Lorelei Bornfleth; Robert K Bolan; Martha Lewis Blum Journal: PLoS One Date: 2017-03-23 Impact factor: 3.240
Authors: Ann M Dennis; Erik Volz; A S Md Simon D W Frost; Mukarram Hossain; Art F Y Poon; Peter F Rebeiro; Sten H Vermund; Timothy R Sterling; Marcia L Kalish Journal: AIDS Res Hum Retroviruses Date: 2018-08-23 Impact factor: 2.205
Authors: Jessica M Fogel; David Bonsall; Vanessa Cummings; Rory Bowden; Tanya Golubchik; Mariateresa de Cesare; Ethan A Wilson; Theresa Gamble; Carlos Del Rio; D Scott Batey; Kenneth H Mayer; Jason E Farley; James P Hughes; Robert H Remien; Chris Beyrer; Christophe Fraser; Susan H Eshleman Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790
Authors: Andrea L Wirtz; Jessica R Iyer; Durryle Brooks; Kimberly Hailey-Fair; Noya Galai; Chris Beyrer; David Celentano; Renata Arrington-Sanders Journal: J Int AIDS Soc Date: 2021-05 Impact factor: 5.396
Authors: Risha Irvin; Theresa Gamble; Jowanna Malone; Zhe Wang; Ethan Wilson; James P Hughes; Jason Farley; Kenneth H Mayer; Carlos Del Rio; D Scott Batey; Vanessa Cummings; Robert H Remien; Chris Beyrer; Chloe L Thio Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 20.999
Authors: Vlad Novitsky; Jon Steingrimsson; Fizza S Gillani; Mark Howison; Su Aung; Matthew Solomon; Cindy Y Won; Amy Brotherton; Rajeev Shah; Casey Dunn; John Fulton; Thomas Bertrand; Anna Civitarese; Katharine Howe; Theodore Marak; Philip Chan; Utpala Bandy; Nicole Alexander-Scott; Joseph Hogan; Rami Kantor Journal: Open Forum Infect Dis Date: 2021-12-07 Impact factor: 4.423
Authors: Davide F Bavaro; Andrea De Vito; Giuseppe Pasculli; Yagai Bouba; Laura Magnasco; Rachele Pincino; Francesco Saladini; Rossana Lattanzio; Romina Corsini; Serena Arima; Maurizio Zazzi; Francesca Incardona; Barbara Rossetti; Antonia Bezenchek; Borghi Vanni; Antonio Di Biagio Journal: J Med Virol Date: 2022-04-09 Impact factor: 20.693
Authors: Susan E Buskin; Richard J Lechtenberg; Francis A Slaughter; Joshua T Herbeck; Roxanne P Kerani; Matthew R Golden; Julia C Dombrowski Journal: PLoS One Date: 2022-08-29 Impact factor: 3.752
Authors: Shelley N Facente; Eduard Grebe; Andrew D Maher; Douglas Fox; Susan Scheer; Mary Mahy; Shona Dalal; David Lowrance; Kimberly Marsh Journal: JMIR Public Health Surveill Date: 2022-03-11